Spinal Muscular Atrophy Market | Spinal Muscular Atrophy

1
Spinal Muscular Atrophy (SMA)
Market Insights, Epidemiology and Market
Forecast- 2028
2
Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy is a genetic disorder
characterized by weakness and wasting (atrophy)
in muscles used for movement (skeletal muscles).
It is caused by a loss of specialized nerve
cells, called motor neurons that control muscle
movement.
SMA is a motor neuron disease caused by
Bi-allelic mutation of survival motor neuron gene
1 (SMN1). There are two identical genes SMN1
(telomeric copy) and SMN2 (centromeric copy)
present at human chromosome 5q13. These genes are
responsible for synthesizing survival motor
neuron protein, which is necessary for the normal
function of motor neurons that control our
muscles.
There are many types of spinal muscular atrophy
(SMA Type 0, I, II, III and IV) that are caused
by changes in the same genes. The types differ in
age of onset and severity of muscle weakness
however, there is overlap between the types.
The weakness tends to be more severe in the
muscles that are close to the center of the body
(proximal) compared to muscles away from the
body's center (distal). The muscle weakness
usually worsens with age.
SMA is the most common genetic disease resulting
in death in infancy and therapies that improve
neuromuscular function as well as maintain
lifelong general health of people living are a
major priority and are an unmet clinical need.
01
05
02
04
03

• DelveInsight 2019 All rights reserved

3
SMA Epidemiology
Survival motor neuron gene 1 (SMN1)
EU-5 Countries Prevalence
SMN1 is considered the active gene for survival
of motor neuron protein production, and more than
98 of patients with spinal muscular atrophy have
an abnormality in both SMN1 genes, which can be
caused by a deletion (95) of exon 7 or other
mutation.
Among the EU5 countries, Germany had the highest
Spinal Muscular Atrophy prevalent population with
1,643 cases in 2017 followed by UK and France. On
the other hand, Spain had the lowest Spinal
Muscular Atrophy prevalence with 468 cases in
2017.
Total prevalent population
US Prevalence
Spinal Muscular Atrophy total prevalent
population was 19,343 in 7 major markets (7MM)
in 2017.
Spinal Muscular Atrophy total prevalent
population was found to be 13,036 in the United
States in 2017.
7MM includes- United States EU 5 (Germany,
France, Spain, Italy, United Kingdom) Japan.

• DelveInsight 2019 All rights reserved

4
SMA Market Outlook
SMA Market Size
Spinal Muscular Atrophy market size was 1,317
Million in seven major markets in 2017 and
is increasing at a CAGR of 10.42 for the study
period (2017-2028).
SMA US Market Size
Spinal Muscular Atrophy total US market size was
USD 892.37 Million in 2017.
SMA in 7MM
Spinal Muscular Atrophy diagnosed prevalent
population in 7MM is expected to increase at a
CAGR of 0.88 for the study period i.e. 2017-2028.
SMA Prevalence
Spinal Muscular Atrophy total prevalence in the
US is expected to increase at a CAGR of 0.77.
7MM includes- United States EU 5 (Germany,
France, Spain, Italy, United Kingdom) Japan.

• DelveInsight 2019 All rights reserved

5
SMA Emerging Drugs and Companies
Drug- RISDIPLAM Company- ROCHE
Drug- AMIFAMPRIDINE PHOSPHATE Company- CATALYST
PHARMACEUTICALS
2010
2011
2012
2013
2014
Drug- ZOLGENSMA Company- NOVARTIS
Drug- RELDESEMTIV Company- ASTELLAS PHARMA

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on Spinal
Muscular Atrophy Market Insights, Epidemiology
Market Forecast-2028 please click the link
below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
MISSION
ABOUT
VISION
To provide insights across the value chain and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.
DelveInsight is a premier Business Consulting and
Market Research firm focused exclusively on the
life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global
Pharmaceutical and Bio-Tech companies formulate
prudent business decisions for improving their
performances to stay ahead of the competitors.
To be the most trusted market research business
consulting firm in the world and to continue
enable the Pharma Bio-Tech companies to achieve
their goals with the best strategic insight and
competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.

• DelveInsight 2019 All rights reserved

8
Service Offerings by DelveInsight
01
05
FORECASTING
OPPORTUNITY ASSESSMENT
02
06
PIPELINE
REPORT STORE
03
07
CONSULTING
COMPETITIVE ANALYSIS
04
08
MARKET INTELLIGENCE
PHARMDELVE

• DelveInsight 2019 All rights reserved

9
Contact Us
blog/delveInsight/
info_at_delveinsight.com
91-11-4568 9769
twitter/delveInsight
LinkedIn/delveInsight
www.delveinsight.com

• DelveInsight 2019 All rights reserved

10
THANK YOU